Table of Contents
ISRN Urology
Volume 2014, Article ID 717295, 4 pages
Review Article

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy

Department of Urology, University Hospital of Wales, Cardiff CF14 4XW, UK

Received 5 November 2013; Accepted 10 December 2013; Published 23 January 2014

Academic Editors: R. Autorino and J. H. Ku

Copyright © 2014 Muhammad Z. Aslam and P. N. Matthews. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Renal cell carcinoma presents with metastatic disease in approximately 30% cases. While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy.